Since Viagra revolutionized men’s sexual health in 1998, women have waited for a comparable treatment focused on physical arousal.
That wait is over with the launch of DARE to PLAY (also called DARE-PLAY), a topical sildenafil cream from Daré Bioscience—the first product using the same active ingredient as Viagra but designed specifically for women’s genital arousal.
Why It Took 30 Years
Viagra (sildenafil) works by increasing blood flow to the genitals. Oral versions for women required high doses, leading to systemic side effects like headaches and nausea. Topical application delivers the drug directly where needed, minimizing risks.
As Daré Bioscience CEO Sabrina Martucci Johnson stated: “When Viagra was approved in 1998, it revolutionized sexual medicine for men. But for women, comparable progress… has stalled for nearly three decades.”
How DARE to PLAY Works
Active Ingredient: Sildenafil (same as Viagra).
Application: Apply a small amount of cream to the genital area before activity.
Effects: Enhances blood flow, boosting sensitivity, arousal, lubrication, and pleasure—often within minutes.
Benefits: Fast-acting, targeted (no full-body effects), and minimal side effects compared to pills.
Other ‘Female Viagra’ Options
While DARE to PLAY targets physical arousal (like men’s Viagra), two FDA-approved drugs address low desire (HSDD):
- Addyi (flibanserin): Daily “pink pill” that balances brain chemicals. Recently expanded (Dec 2025) to postmenopausal women under 65.
- Vyleesi (bremelanotide): As-needed injection for premenopausal women.
DARE to PLAY is currently available via prescription in select states as a compounded product (not yet fully FDA-approved but manufactured under strict guidelines), with wider rollout in 2026.
This breakthrough finally gives women a direct, arousal-focused option—empowering confidence and pleasure on their terms. Consult a doctor to see if it’s right for you!